(Q41363536)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26367239%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

title

Outcome of patients with relapsed diffuse large B-cell lymphoma who fail second-line salvage regimens in the International CORAL study (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26367239%20AND%20SRC:MED&resulttype=core&format=json

diffuse large B-cell lymphoma

24 February 2020

main subject

1 reference

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26367239%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

Marek Trněný

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26367239%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

Noel Jean Milpied

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26367239%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

John Radford

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26367239%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

5

D Linch

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26367239%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

author name string

E Van Den Neste

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26367239%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

N Schmitz

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26367239%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

D Gill

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26367239%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

N Ketterer

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26367239%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

O Shpilberg

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26367239%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

U Dührsen

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26367239%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

D Ma

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26367239%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

J Brière

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26367239%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

C Thieblemont

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26367239%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

G Salles

15

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26367239%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

C H Moskowitz

16

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26367239%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

B Glass

17

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26367239%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

C Gisselbrecht

18

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26367239%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

language of work or name

English

0 references

publication date

14 September 2015

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26367239%20AND%20SRC:MED&resulttype=core&format=json

Bone Marrow Transplantation

24 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26367239%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

volume

51

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26367239%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26367239%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

page(s)

51-57

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26367239%20AND%20SRC:MED&resulttype=core&format=json

Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma

24 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2015.213

Rituximab improves the treatment results of DHAP-VIM-DHAP and ASCT in relapsed/progressive aggressive CD20+ NHL: a prospective randomized HOVON trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2015.213

Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2015.213

Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2015.213

Rituximab maintenance therapy after autologous stem-cell transplantation in patients with relapsed CD20(+) diffuse large B-cell lymphoma: final analysis of the collaborative trial in relapsed aggressive lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2015.213

Early failure of frontline rituximab-containing chemo-immunotherapy in diffuse large B cell lymphoma does not predict futility of autologous hematopoietic cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2015.213

High-dose therapy and autologous stem cell transplantation in first relapse for diffuse large B cell lymphoma in the rituximab era: an analysis based on data from the European Blood and Marrow Transplantation Registry

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2015.213

Randomized comparison of gemcitabine, dexamethasone, and cisplatin versus dexamethasone, cytarabine, and cisplatin chemotherapy before autologous stem-cell transplantation for relapsed and refractory aggressive lymphomas: NCIC-CTG LY.12.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2015.213

Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2015.213

The germinal center/activated B-cell subclassification has a prognostic impact for response to salvage therapy in relapsed/refractory diffuse large B-cell lymphoma: a bio-CORAL study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2015.213

Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2015.213

Outcomes of patients with relapsed/refractory diffuse large B-cell lymphoma with progression of lymphoma after autologous stem cell transplantation in the rituximab era.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2015.213

Chemoresistant or aggressive lymphoma predicts for a poor outcome following reduced-intensity allogeneic progenitor cell transplantation: an analysis from the Lymphoma Working Party of the European Group for Blood and Bone Marrow Transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2015.213

Outcomes of adults with active or progressive hematological malignancies at the time of allo-SCT: a survey from the Société Française de Greffe de Moelle et de Thérapie Cellulaire (SFGM-TC).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2015.213

Impact of pretransplantation conditioning regimens on outcomes of allogeneic transplantation for chemotherapy-unresponsive diffuse large B cell lymphoma and grade III follicular lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2015.213

Response to second-line therapy defines the potential for cure in patients with recurrent diffuse large B-cell lymphoma: implications for the development of novel therapeutic strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2015.213

Utility of subsequent conventional dose chemotherapy in relapsed/refractory transplant-eligible patients with diffuse large B-cell lymphoma failing platinum-based salvage chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2015.213

MYC protein expression and genetic alterations have prognostic impact in patients with diffuse large B-cell lymphoma treated with immunochemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2015.213

Obinutuzumab (GA101) monotherapy in relapsed/refractory diffuse large b-cell lymphoma or mantle-cell lymphoma: results from the phase II GAUGUIN study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2015.213

Ofatumumab in combination with ICE or DHAP chemotherapy in relapsed or refractory intermediate grade B-cell lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2015.213

Combination of ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for treatment-naive patients with CD20-positive B-cell non-Hodgkin lymphoma: a non-randomised, phase 1b study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2015.213

High-throughput combinatorial screening identifies drugs that cooperate with ibrutinib to kill activated B-cell-like diffuse large B-cell lymphoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2015.213

Futility of relapsed diffuse large B cell lymphoma transplantation?

21 January 2018

1 reference

12 December 2020

Allogeneic stem-cell transplantation as salvage therapy for patients with diffuse large B-cell non-Hodgkin's lymphoma relapsing after an autologous stem-cell transplantation: an analysis of the European Group for Blood and Marrow Transplantation Reg

1 reference

12 December 2020

Improving survival and preventing recurrence of diffuse large B-cell lymphoma in younger patients: current strategies and future directions

1 reference

12 December 2020

Should we replace dexamethasone, cytarabine, and cisplatin for relapsed lymphoma?

1 reference

12 December 2020

Rituximab after lymphoma-directed conditioning and allogeneic stem-cell transplantation for relapsed and refractory aggressive non-Hodgkin lymphoma (DSHNHL R3): an open-label, randomised, phase 2 trial

1 reference

12 December 2020

The role of autologous stem cell transplantation in the treatment of diffuse large B-cell lymphoma

1 reference

12 December 2020

Is there any role for transplantation in the rituximab era for diffuse large B-cell lymphoma?

1 reference

12 December 2020

Effectiveness of second line salvage chemotherapy with ifosfamide, carboplatin, and etoposide in patients with relapsed diffuse large B-cell lymphoma not responding to cis-platinum, cytosine arabinoside, and dexamethasone

1 reference

12 December 2020

Conventional second-line salvage chemotherapy regimens are not warranted in patients with malignant lymphomas who have progressive disease after first-line salvage therapy regimens

1 reference

12 December 2020